News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Alcon Laboratories, Inc. Directors Say Novartis Corporation Bid Grossly Inadequate
January 20, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Novartis AG's offer to buy out minority shareholders in Alcon Inc is "grossly inadequate", independent directors of the eyecare group said on Wednesday, setting the stage for a prolonged battle.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Immunology and inflammation
Neurocrine Goes to China To Grow Pipeline in up to $881M TransThera Deal
November 3, 2025
·
1 min read
·
Dan Samorodnitsky
Neuroscience
Roche Piles $55M Into Blood-Brain Barrier Tech With Manifold
November 3, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
UPDATE: Pfizer Files Lawsuits Against Novo Nordisk, Metsera To Stop Rival Bid
November 3, 2025
·
4 min read
·
Tristan Manalac
Editorial
Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian
October 31, 2025
·
3 min read
·
Annalee Armstrong